Pompe disease: 2026 so far

Comparative and switch data expanded, with benefits often modest.

In the months covered, several analyses added more direct comparisons between enzyme regimens in late-onset Pompe disease. One-year trial-derived comparisons more often favored cipaglucosidase alfa plus miglustat over alglucosidase alfa for average walking and breathing outcomes. Longer-term summaries still described gradual change over years. Real-world switch studies often described stability rather than dramatic improvement. This included routine-care follow-up after switching to avalglucosidase alfa or cipaglucosidase alfa plus miglustat. Registry data suggested that walking decline before switching to avalglucosidase alfa could shift to stabilization or improvement in the first year after switching. Breathing measures often changed little over 1 to 2 years. These reports help set expectations: structured datasets may show average differences between regimens, while routine care after switching often looks more like staying stable than making a big jump.

Research covered in: February 2026, March 2026, July 2026

Timing signals strengthened, especially for infant heart outcomes.

So far in 2026, real-world reports in infantile-onset Pompe disease repeatedly linked a very early start of alglucosidase alfa (including within the first month) with faster improvement toward more normal heart ultrasound measurements. Even in cohorts using immune tolerance approaches and higher-frequency dosing, longer-term outcomes were still uneven in some children. This included later ventilator dependence or death in long follow-up. That pattern suggests that an early heart response does not remove all later risks. A small newborn-screening-identified symptomatic late-onset pediatric series also reported motor improvement after early ERT, but it did not include a comparison group. In these observational reports, the most consistent near-term finding was faster heart improvement with earlier infant treatment, while longer-term function and survival still varied from child to child.

Research covered in: January 2026, April 2026, May 2026

Immune variability became more measurable, with antibody-linked effects.

In the available months, several studies pointed to immune response as a practical reason ERT experiences can differ. High anti-drug antibodies were reported in infant cohorts, including some CRIM-positive children. Adult data linked higher antibody titres with more infusion-associated reactions. In classic infantile Pompe disease, a small study reported that very high antibody levels were often associated with reduced enzyme availability after infusion. This was supported by blood-based exposure measures and cell experiments in subsets. Add-on immune approaches showed mixed signals. In one profiling study, enzyme therapy combined with transient low-dose methotrexate was followed by less inflammatory immune patterns and decreased urinary Glc4, yet some patients still developed or increased antibodies. Taken together, these reports suggest that antibody monitoring and infusion-reaction management can strongly shape how smoothly ERT is given and, for some individuals, how much enzyme is available after an infusion.

Research covered in: January 2026, April 2026, May 2026, September 2026

More studies documented real-life supports beyond enzyme choice.

A small European review described people who continued ERT during pregnancy. It was not associated with reported infusion reactions or reported mother-child harms. The review did describe mild dips in walking distance or breathing tests during pregnancy, with recovery toward pre-pregnancy levels when follow-up was available. Several reports also highlighted respiratory support needs. Pediatric sleep studies found obstructive sleep apnea (blocked breathing during sleep) or elevated carbon dioxide in subsets. An adult case described rapid improvement in respiratory failure after starting noninvasive ventilation (breathing support through a mask). Longer-term infant follow-up also described sleep-breathing abnormalities emerging around school age. In addition, a large adult cross-sectional study reported chronic nociceptive musculoskeletal pain (ongoing pain from muscles and joints) was very common. It did not meaningfully track with strength, walking tests, or muscle ultrasound at a single visit. A small case series reported a carbohydrate-restricted, high-fat, high-protein diet as feasible and generally well tolerated, but it did not include a control group. Overall, these studies add to the picture that sleep breathing, ventilation, pain, and nutrition can matter alongside disease-modifying therapy, even though most evidence here is still observational or case-based.

Research covered in: June 2026, August 2026, September 2026

Candidate biomarkers and imaging expanded, with early validation signals.

Across January 2026 to September 2026, several candidate monitoring tools were described. In a 4-year follow-up study, higher baseline urinary Glc4 levels were linked to greater later decline in walking distance and to more muscle fat replacement. Quantitative muscle MRI fat fraction (MRI measurement of how much fat has replaced muscle) tracked severity in a cross-sectional view and increased over time in a small 2-year adult follow-up. For breathing, studies suggested diaphragm or ventilation changes may be captured by tools beyond standard spirometry (breathing tests). These included real-time diaphragm MRI, PREFUL lung MRI, and oscillometry (breathing test that measures airway resistance) patterns that did not normalize even when FVC rose after air-stacking. An expert paper also proposed ranges for defining 'stability' versus 'concerning decline' on ERT. For infantile-onset CNS involvement, plasma GFAP (a blood marker linked to brain support cells) tracked white matter changes on brain MRI in one dataset. For day-to-day care, these measures mainly affect research and follow-up planning right now: they may pick up changes that routine clinic tests miss, but most still need larger studies before they can be used confidently for individual predictions.

Research covered in: January 2026, February 2026, March 2026, June 2026, August 2026